home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

305 rows where filing_period = "third_quarter", filing_year = 2018 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 305 ✖

filing_year 1

  • 2018 · 305 ✖

filing_period 1

  • third_quarter · 305 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2176352 PD FRAZER CONSULTING, INC. 2cffb37f-f4c9-4451-b930-0affe4d91959 3T PD FRAZER CONSULTING, INC. 65998 CANADA INTERNATIONAL PHARMACY ASSOCIATION 2018 third_quarter PHA Support intent of H.R.1480 Safe and Affordable Drugs from Canada Act of 2017 Support intent of S.92 Safe and Affordable Drugs from Canada Act of 2017 Support intent of H.R. Affordable and Safe Prescription Drug Importation Act Support of S.469 Affordable and Safe Prescription Drug Importation Act HOUSE OF REPRESENTATIVES,SENATE 10000   0 1 2018-07-31T16:23:44.210000-04:00
2176881 LINCOLN PARK GROUP L.L.C. 1fb42e2c-d26a-4f0d-93c6-6502f2a71a9e 3T LINCOLN PARK GROUP L.L.C. 401104374 PD FRAZER CONSULTING, INC. ON BEHALF OF CANADA INTERNATIONAL PHARMACY ASSOC. 2018 third_quarter PHA Support intent of H.R.1480 Safe and Affordable Drugs from Canada Act of 2017 Support intent of S.92 Safe and Affordable Drugs from Canada Act of 2017 Support intent of H.R. Affordable and Safe Prescription Drug Importation Act Support of S.469 Affordable and Safe Prescription Drug Importation Act; HR 5752 Stop Illicit Drug Importation Act. HOUSE OF REPRESENTATIVES,SENATE     0 1 2018-08-03T09:48:36.853000-04:00
2179531 RED+BLUE STRATEGIES 4d93e9e1-902b-4f97-980a-bdd5312e3704 Q3 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2018 third_quarter PHA S. 2553 - Know the Lowest Price Act of 2018- Support of the elimination of "gag clauses" in Medicare Part D. S. 2554 - Patient Right to Know Act - Support of the elimination of "gag clauses" in private market drug benefits. H.R. 6 - Support for Patients and Communities Act - Issues related to ensuring safe prescribing of opioids and other pharmaceuticals that can drive addiction. S. 3120 - Helping to End Addition and Lessen Substance Use Disorders Act - Issues related to ensuring safe prescribing of opioids and other pharmaceuticals that can drive addiction. S. 2460/H.R. 3528 - Every Prescription Conveyed Securely Act - support for a bill that would require electronic prescribing for opioids. CMS regulations related to the Medicare Part D program and role of Prescription Drug Plans. S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. H.R. 3447 - Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 - Working to explain the need for safe and confidential data sharing between Medicare part A, B, and D to ensure better coordination of patient care. Issues related to Direct and Indirect Renumeration policies and their impact on consumers. The Trump Administration's Blueprint for Controlling Prescription Drug Prices - Issues related to the role PBMs can play in controlling the price of prescription medications in the United States. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-10-02T15:21:15.300000-04:00
2179545 RED+BLUE STRATEGIES fde830ae-0354-45e8-b7a3-283aec7ad0d6 Q3 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2018 third_quarter PHA H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions. S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions. H.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety. S. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of " gag clauses" in the Medicare Part D program. S. 2554 - Patient Right to Know Act Drug Prices Act of 2018 - Support for for the elimination of "gag clauses" in the private insurance market. CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs). S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D. Trump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-10-02T15:38:20.660000-04:00
2179548 RED+BLUE STRATEGIES 88d28e1e-52e8-475f-b12b-b7f5e3f0a3d3 Q3 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2018 third_quarter PHA H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on public health. S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on public health. S. 2315 - The Over the Counter Drug Safety Innovation and Reform Act - Support for amending and improving OTC Monograph Reform. S. 2852 - the Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to the continues attention required to antibiotic resistance as a public health threat and policies to ensure the adequacy and development of antibiotics to ward against threats to the common good. Trump Administration's Blueprint for lowering the price of prescription medications in the United States. CMS regulations related to Medicare Part D and promulgation of laws related to curbing substance use disorder among Medicare beneficiaries. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement Issues related to over the counter medications and supplements. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-10-02T15:42:21.617000-04:00
2179867 AMERICAN CAPITOL GROUP 84d99f14-21e9-4ae0-a546-98f9a622f3e3 Q3 AMERICAN CAPITOL GROUP 305852 CARDINAL HEALTH 2018 third_quarter PHA Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services; Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-10-03T16:16:03.210000-04:00
2179884 HB STRATEGIES a7a6840c-8ca1-43d7-918e-d88495661dc1 Q3 HB STRATEGIES 401104718 BAYER U.S. LLC 2018 third_quarter PHA Issues related to tax, trade and pharmaceutical policy HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-10-03T16:29:12.197000-04:00
2179901 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 724542db-bc37-41c5-939c-75a3edc0153d Q3 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 11003 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 2018 third_quarter PHA CCAGW and NTU Regarding H.R. 6642 HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2018-10-03T16:59:21.467000-04:00
2180294 CHATMAN, LLC 12475c5c-2f50-489f-9a22-414f81138698 Q3 CHATMAN, LLC 400678024 LIVINGSTON GROUP FOR RUSH UNIVERSITY MEDICAL CENTER 2018 third_quarter PHA Support 340B program in HRSA. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-10-04T20:02:19.630000-04:00
2180297 CHATMAN, LLC 8943b13c-aba5-4eec-9312-89452f6bc2f2 3A CHATMAN, LLC 400678024 LIVINGSTON GROUP FOR RUSH UNIVERSITY MEDICAL CENTER 2018 third_quarter PHA Support 340B program in HRSA. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-10-04T20:14:20.663000-04:00
2180353 KATE MOSS cd919f2b-59b8-44cc-b9dc-10b8e7315ac3 Q3 KATE MOSS 25988 CVS HEALTH 2018 third_quarter PHA Legislation impacting PBMs and drug pricing HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-10-05T09:50:59.723000-04:00
2180565 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION d64f6b6a-1f98-472a-a7f9-853fbbd31b47 Q3 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2018 third_quarter PHA Answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector. HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2018-10-05T14:59:13.197000-04:00
2180666 BROYDRICK & ASSOCIATES ea300b8b-3082-4a74-8907-9b730ec334f0 Q3 BROYDRICK & ASSOCIATES 7268 EXELA PHARMA SCIENCES 2018 third_quarter PHA Drug shortages and FDA approval, USTR acceptance. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2018-10-05T18:23:11.293000-04:00
2180680 BROYDRICK & ASSOCIATES b402a913-d411-42bd-a853-eb99d3843fe0 Q3 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2018 third_quarter PHA Funding for a new drug for PTSD. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2018-10-05T18:38:21.623000-04:00
2180929 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION f7cc014e-b53b-42c1-9be6-ecb93cb7869f Q3 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 401103437 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 2018 third_quarter PHA FDA Listening Session on Compounding Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   10000 0 0 2018-10-08T15:27:07.087000-04:00
2181116 AMERICAN COLLEGE OF CLINICAL PHARMACY 61fbbf6e-5870-49bb-b3a5-341437eec39d Q3 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2018 third_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2018-10-09T10:59:25.970000-04:00
2181134 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING be459d23-1aae-446b-9362-5043b2705bc1 Q3 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2018 third_quarter PHA Compounding of radiopharmaceuticals. Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE   30000 0 0 2018-10-09T11:24:35.817000-04:00
2181224 MR. VINCENT A. PANVINI 51359e3b-c249-4194-8927-9717c4f7449f Q3 MR. VINCENT A. PANVINI 401008845 PHRMA 2018 third_quarter PHA Medicare Part D HOUSE OF REPRESENTATIVES,SENATE     0 0 2018-10-09T12:25:19.510000-04:00
2181276 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) e8f89747-6fc9-4fa2-b03a-a019db66fbac Q3 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 24486 INOVIO PHARMACEUTICALS 2018 third_quarter PHA Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-10-09T13:43:54.990000-04:00
2181348 TAUZIN STRATEGIC NETWORKS da4c9d4b-9483-4de9-b45c-c20e19e458e5 Q3 TAUZIN STRATEGIC NETWORKS 400786367 CAPTURERX 2018 third_quarter PHA Issues related to the 340b program HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-10-09T14:23:31.820000-04:00
2181698 THE KUTLER GROUP 9a04aeed-86b3-41fc-96ba-2670e50223b8 Q3 THE KUTLER GROUP 401103966 PRIME THERAPEUTICS 2018 third_quarter PHA Patient Right to Know Drug Prices Act Prescription Transparency Act CREATES Act HOUSE OF REPRESENTATIVES,SENATE 24000   0 0 2018-10-10T10:21:18.097000-04:00
2181938 BROWN RUDNICK LLP 42629887-8f5d-4168-a84d-70bba16a0156 Q3 BROWN RUDNICK LLP 287895 PRIME THERAPEUTICS 2018 third_quarter PHA S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-10-10T13:27:42.463000-04:00
2182119 ROWLAND STRATEGY GROUP LLC dd1bb0c4-1b35-4848-9176-889265878484 Q3 ROWLAND STRATEGY GROUP LLC 401104274 RAI SERVICES COMPANY 2018 third_quarter PHA Departments of Labor, Health and Human Services, and Related Agencies appropriations; provisions related to innovative response platforms for vaccines and drugs. HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2018-10-10T16:45:38.090000-04:00
2182222 WAXMAN STRATEGIES 3a35f6ab-dcc9-499f-80ec-c9909ba942e2 Q3 WAXMAN STRATEGIES 401103693 340B HEALTH 2018 third_quarter PHA Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 HOUSE OF REPRESENTATIVES,SENATE 18750   0 0 2018-10-11T09:00:57.097000-04:00
2182293 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 50ac9809-9d19-43e8-96a7-9d77f9cdedc4 Q3 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 26672 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2018 third_quarter PHA H.R. 1245/S. 469 The Affordable and Safe Prescription Drug Importation Act H.R. 1316 - Prescription Drug Price Transparency Act H.R. 749 Lower Drug Costs Through Competition H.R.2430/S. 934 - FDA Reauthorization Act of 2017 H.R. 4841 - Standardizing Electronic Prior Authorization for Safe Prescribing Act H.R. 6733 - Know the Cost Act H.R. 6143/ S. 2554 - Patient Right to Know Drug Prices Act H.R. 6144/ S. 2553 - Know the Lowest Price Act H.R. 6641 - True Cost-sharing of Seniors Drugs Transparency (True COST) Act H.R. 5989 - Fair Pricing Act Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   440000 0 0 2018-10-11T10:31:39.797000-04:00
2182349 CAPITOL HILL CONSULTING GROUP f20c9597-84bf-44dc-b3bc-ef3de7a0a942 Q3 CAPITOL HILL CONSULTING GROUP 72053 PURDUE PHARMA LLP 2018 third_quarter PHA Controlled Drug Substances Act (21 USC 13) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-10-11T11:08:03.083000-04:00
2182714 WAXMAN STRATEGIES 6d1e4738-944b-4ac8-a6be-9f085f36ea90 Q3 WAXMAN STRATEGIES 401103693 MEDICINES360 2018 third_quarter PHA Issues impacting the 340B drug discount program; SERV Communities Act HR 6071 HOUSE OF REPRESENTATIVES     0 0 2018-10-11T15:35:29.053000-04:00
2182915 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 8c0f0b30-2aa6-46f2-841b-f8b550a6ce97 Q3 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2018 third_quarter PHA 340B drug pricing, PREA, CAR-T Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office   50890 0 0 2018-10-12T09:20:02.407000-04:00
2183159 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 7bc43a37-a519-46f5-ada8-e57a65056287 Q3 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2018 third_quarter PHA Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. S. 2825/H.R. 6378 -- Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018. To reauthorize certain programs under the Pandemic and All-Hazards Preparedness Reauthorization Act. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of   198000 0 0 2018-10-12T11:31:27.360000-04:00
2183285 MCDERMOTT+ LLC 19017d8e-b16c-49eb-b621-e44550cf6584 Q3 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2018 third_quarter PHA Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-10-12T12:42:12.507000-04:00
2183315 ACG ADVOCACY 963fc430-23bf-41e5-b72e-09a685245d68 Q3 ACG ADVOCACY 2057 WALGREEN CO. 2018 third_quarter PHA Competition Policy Issues. Drug Pricing Policy Issues. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-10-12T12:54:22.727000-04:00
2183588 ACADEMY OF MANAGED CARE PHARMACY 0092ee42-d90c-4005-bd6f-6eb95d8bd5ce Q3 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2018 third_quarter PHA Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2018-10-12T16:45:20.873000-04:00
2183736 INDEPENDENT PHARMACY COOPERATIVE 99a16a6c-8268-420f-bb33-783c447bc803 Q3 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2018 third_quarter PHA Support S. 2553, the Know the Lowest Price Act of 2018, and S. 2554, the Patient Right to Know Drug Prices Act, which give community pharmacists more flexibility in informing patients they could pay less out of pocket for a prescription than by using their health insurance. Medicare CONTRACT YEAR 2019 POLICY AND TECHNICAL CHANGES comments. Support all drug price concessions at the point of sale. Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act Support S.413/H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act. Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision. Support S. 413 / H.R. 1038 the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act" Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2018-10-13T10:26:03.607000-04:00
2183771 THE MATHIS HARPLE GROUP 529d5697-a78a-40d9-874e-cf52c1f70e7f Q3 THE MATHIS HARPLE GROUP 322911 PILMA 2018 third_quarter PHA Medicare Part D Donut Hole HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-10-13T14:06:25.140000-04:00
2183835 BROWN RUDNICK LLP 21a2ea33-9248-4ee6-8a9f-bf6dea058e42 Q3 BROWN RUDNICK LLP 287895 HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC 2018 third_quarter PHA S.469-The Affordable and Safe Prescription Drug Importation Act; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-10-14T13:42:03.457000-04:00
2183873 ROCK & ASSOCIATES 4e54e8c4-998c-4577-9bde-dcb1b71fc0e0 Q3 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2018 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-10-14T23:17:25.633000-04:00
2183877 ROCK & ASSOCIATES f6d507f2-ad41-4bdb-a986-1e207ecf9d17 Q3 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2018 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-10-14T23:19:26.587000-04:00
2183879 ROCK & ASSOCIATES afef92c4-be59-47bb-8f3d-97baca452b70 Q3 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2018 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-10-14T23:20:27.400000-04:00
2183883 ROCK & ASSOCIATES 2e3ff669-3730-404a-bec8-f7846d42ac64 Q3 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2018 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-10-14T23:20:28.120000-04:00
2183885 ROCK & ASSOCIATES 632c04af-82fb-418e-8446-ed01cfb63a91 Q3 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2018 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-10-14T23:21:28.823000-04:00
2183888 ROCK & ASSOCIATES dcb08340-7434-4b68-b40d-3e42343990b7 Q3 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2018 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-10-14T23:22:29.527000-04:00
2183892 ROCK & ASSOCIATES c61f3ff2-25ac-4c38-ac52-31406e6a1381 Q3 ROCK & ASSOCIATES 33545 PRECISION PHARMACY 2018 third_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2018-10-14T23:23:30.307000-04:00
2183915 RED+BLUE STRATEGIES 926d9721-2f7d-450e-baa2-0f16f0a11fd1 Q3 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2018 third_quarter PHA Executive and Legislative initiatives to allow the biosimilars market place to succeed in the United States. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-10-15T08:52:44.727000-04:00
2183963 COVINGTON & BURLING LLP 4140b7bb-5c51-4ebe-bdd1-88af6743bc1d Q3 COVINGTON & BURLING LLP 11195 FLEXION THERAPEUTICS, INC. 2018 third_quarter PHA Education and support for public policies that promote the development, use, coverage and reimbursement of novel, non-opioid pain therapies, including FDA Opioid Sparing legislation. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-10-15T10:23:11.977000-04:00
2183998 LUPIN PHARMACEUTICALS INC 64fa9d70-bff8-4383-9a1c-f89e5b2e3c39 Q3 LUPIN PHARMACEUTICALS INC 401104766 LUPIN PHARMACEUTICALS INC 2018 third_quarter PHA CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues. PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity. CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis. HOUSE OF REPRESENTATIVES,SENATE   83325 0 0 2018-10-15T10:49:27.650000-04:00
2184970 FLYNN & ASSOCIATES, INC. c81bd0b0-e244-41fd-8d8c-a0284f46b9a1 Q3 FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2018 third_quarter PHA Childrens Health Insurance Program Importation of drugs from Canada Medicare Part D - Rebates HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-10-16T09:24:51.567000-04:00
2185016 LINCOLN PARK GROUP L.L.C. f4cf3c39-cb6b-4d69-8c75-8b5a073cdd74 Q3 LINCOLN PARK GROUP L.L.C. 401104374 CANADIAN INTERNATIONAL PHARMACY ASSOCIATION 2018 third_quarter PHA Support intent of H.R.1480 Safe and Affordable Drugs from Canada Act of 2017 Support intent of S.92 Safe and Affordable Drugs from Canada Act of 2017 Support intent of H.R. Affordable and Safe Prescription Drug Importation Act Support of S.469 Affordable and Safe Prescription Drug Importation Act; HR 5752 Stop Illicit Drug Importation Act; Support of HR 6 Patients and Communities Act. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-10-16T09:55:10.400000-04:00
2185087 MANATT, PHELPS, AND PHILLIPS 7c27bbf3-e77d-4ed0-b064-282b2afe84f4 Q3 MANATT, PHELPS, AND PHILLIPS 23645 NEKTAR THERAPEUTICS 2018 third_quarter PHA FDA oversight of certain pain reliever products Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 108000   0 0 2018-10-16T10:28:41.107000-04:00
2185184 LEHIGH VALLEY HEALTH NETWORK 3e108113-3d7c-4ba0-85b3-a2669d44ef21 Q3 LEHIGH VALLEY HEALTH NETWORK 40041332 LEHIGH VALLEY HEALTH NETWORK 2018 third_quarter PHA researching 340 B program       0 0 2018-10-16T11:16:18.427000-04:00
2185327 ZHF CONSULTING LLC 1f268a32-dc84-47b6-96f1-0bc0459123c1 Q3 ZHF CONSULTING LLC 401103689 MEDISCA, INC. 2018 third_quarter PHA Opioid crisis/alternative pain medication HOUSE OF REPRESENTATIVES,SENATE 22500   0 0 2018-10-16T11:54:09.850000-04:00
2185745 BUCHANAN INGERSOLL & ROONEY PC 6fe74fae-ce6f-4ff9-b166-a8cf1ea22cb8 Q3 BUCHANAN INGERSOLL & ROONEY PC 55291 TISSUEGENE, INC. 2018 third_quarter PHA Federal government relations service, strategy development and implementation relating to regenerative medicine products. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-10-16T14:05:00.897000-04:00
2185817 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS c92bba0a-69dd-414a-8f42-2e8b4b1e9f91 Q3 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2018 third_quarter PHA Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with Congress on compounding. Communicated with House and Senate offices on drug shortages.Communication with DEA on opioid shortage of generic injectables. Support for S. 974, Creating and Restoring Equal Access to Equivalent Samples Act of 2018, and H.R. 6142, Reducing Drug Waste Act of 2018. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE   290000 0 0 2018-10-16T14:22:28.587000-04:00
2185931 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 5769b95e-d14a-4f82-9282-a84a5d63ed0f Q3 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2018 third_quarter PHA HR 4392 To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. HR 6082 Overdose Prevention and Patient Safety Act; support treatment options/funding for reduction and treatment of opioid addiction. Opposition to any provision in any bill to reduce the scope and use of the 340B Drug Discount benefit. HOUSE OF REPRESENTATIVES,SENATE   11486 0 0 2018-10-16T14:51:11.357000-04:00
2186266 LUNGREN LOPINA LLC 971c4dab-3b08-4efe-8138-5a8d91691e89 Q3 LUNGREN LOPINA LLC 401103314 AMPAC FINE CHEMICALS 2018 third_quarter PHA Fair treatment for US pharmaceutical ingredients HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-10-16T15:51:50.333000-04:00
2186299 MERCURY PUBLIC AFFAIRS, LLC 6dbf9271-1c23-415d-962e-b488280dea0a Q3 MERCURY PUBLIC AFFAIRS, LLC 70175 MORRIS AND DICKSON 2018 third_quarter PHA IT Help RE Improper Prescriptions Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),Justice, Dept of (DOJ),Office of Natl Drug Control Policy (NDCP),White House Office 20000   0 0 2018-10-16T16:03:06.100000-04:00
2186588 MCDERMOTT WILL & SCHULTE LLP 5359526f-1f20-4e31-afc7-700edd12b29f Q3 MCDERMOTT WILL & SCHULTE LLP 24338 MAXOR NATIONAL PHARMACY SERVICES, LLC 2018 third_quarter PHA Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, the 340B Program. HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 50000   0 0 2018-10-16T18:03:54.620000-04:00
2186753 TRAVERE THERAPEUTICS 56db97d3-cddb-4921-946b-6c43e79a2049 Q3 TRAVERE THERAPEUTICS 401104190 TRAVERE THERAPEUTICS 2018 third_quarter PHA Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, opioid legislation provisions related to opioid sparing, FAST Generics and CREATES Acts, FDA issues HOUSE OF REPRESENTATIVES,SENATE   220000 0 0 2018-10-16T22:45:04.840000-04:00
2186848 NOVO NORDISK INC. d2141923-cfc8-4f86-837f-1214b2b6b79a Q3 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2018 third_quarter PHA Issues related to P.L. 115-52 (H.R. 2430/S. 934) FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S.771 Improving Access To Affordable Prescription Drugs Act; H.R. 4710, the 340B Protecting Access for the Underserved and Safety-Net Entities Act (340 PAUSE Act)and other issues related to 340B program Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Veterans Affairs, Dept of (VA)   700000 0 0 2018-10-17T08:52:57.437000-04:00
2186998 ACADEMY OF MANAGED CARE PHARMACY 728b22c6-a684-4909-9437-3d8cc5bde4e9 3A ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2018 third_quarter PHA Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2018-10-17T10:09:55.870000-04:00
2187005 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 6679ae1c-7cf2-4f30-80bc-acf724891370 Q3 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2018 third_quarter PHA Ensuring Patient Access and Effective Enforcement Act (Public Law 114-145); Opioid Abuse - General issues related to opioid abuse (HR6, HR 6779, HR 6600, S 2838; S 2837, S 3120, S 2680, S 3282); Importation of Prescription Drugs (S 469, S 771, HR 1776, HR 1245, HR 934, HR 1480, S 92, S 64), Implementation of Public Law 113-54 (DSCSA) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   292365 0 0 2018-10-17T10:13:58.777000-04:00
2187076 PUBLIC CITIZEN 02c64356-a8dd-4dc0-a623-ac94ec8a67eb Q3 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2018 third_quarter PHA S. 2852/HR 3678-Pandemic and all-hazards preparedness and advancing innovation act of 2018, HR 6294-REVAMP Act, Medicare Part D negotiation, prescription drug pricing, HR 6505-Medicare negotiation and competitive licensing act, HR 6577-PRICED act, HR 6576-Drug Price Transparency in Communications act, medicare prescription drug savings and choice act, HR 1223/S 1509 OPEN Act, S 1369-Stop Price gouging act. HOUSE OF REPRESENTATIVES,Office of Government Ethics (OGE),Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR)   50000 0 0 2018-10-17T10:26:15.573000-04:00
2187086 ICE MILLER LLP 57abfffe-d7d1-485c-839f-e0d115e84160 Q3 ICE MILLER LLP 67854 ELI LILLLY AND COMPANY 2018 third_quarter PHA Issues related to pharmaceutical research and manufacturing Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE,Vice President of the U.S.     0 0 2018-10-17T10:28:19.620000-04:00
2187179 AARP 16052389-8f22-4052-a030-2412082b615b Q3 AARP 1694 AARP 2018 third_quarter PHA Discussed efforts to include harmful prescription drug policies in NAFTA with House and Senate staff. H.R. 2212/ S. 974, CREATES Act - Discussed support of bill. H.R. 2439/S.1131, FAIR Drug Pricing Act - Discussed support of bill. S. 124, The Preserve Access to Affordable Generics Act - Discussed support of bill. Part D Deal in Bipartisan Budget Act, Met with House offices to reiterate our support for the deal; sent multiple letters to House and Senate leadership; discussed support for the deal with House and Senate staff. Discussed the Presidents Prescription Drug Blueprint and RFI. S. 1091, the Supporting Grandparents Raising Grandkids Act - Advocated for passage of bill. S. 2553, Know the Lowest Price Act - Endorsed legislation. S.2554, Patient Right to Know Act - Endorsed legislation. Discussed opioid abuse legislation to address opioid abuse and misuse. Discussed possible ways to improve Medicare Part D. Discussed Rx Price Watch Reports and the impact of high drug costs. Discussed drug pricing reforms AARP supports, including secretarial negotiation, importation, reducing exclusivity for biologics, and ending pay-for-delay deals. Discussed family caregiving, opioids, and Supporting Grandparents Raising Grandchildren Act (P.L. 115-196, S. 1091/H.R. 3105). Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Federal Highway Administration (FHA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Labor, Dept of (DOL),Natl Highway Traffic Safety Administration (NHTSA),Securities & Exchange Commission (SEC),SENATE,Treasury, Dept of,White House Office   1740000 0 0 2018-10-17T10:46:51.623000-04:00
2187498 UNIVERSITY OF IOWA d636c755-9a57-4c37-8f49-c2f1a4c99ae4 Q3 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2018 third_quarter PHA FY 19 appropriations for NIH Support for 340B program Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Energy, Dept of,Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT)   50000 0 0 2018-10-17T11:32:45.247000-04:00
2187603 NATIONAL HOME INFUSION ASSOCIATION 8dc45e1a-becb-409e-96c5-a5973928ce8e Q3 NATIONAL HOME INFUSION ASSOCIATION 40047365 NATIONAL HOME INFUSION ASSOCIATION 2018 third_quarter PHA Lobbied on FDA Proposed Draft State Memorandum of Understanding Lobbied on FDA Proposed Guidance on Insanitary Conditions Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office   77000 0 0 2018-10-17T11:51:12.030000-04:00
2187633 POLITICAL CAPITAL, LLC f202d19b-2391-4f39-8fe6-fa7e900a2719 Q3 POLITICAL CAPITAL, LLC 401104260 MEDISCA INC 2018 third_quarter PHA DQSA Oversight HR 2871 Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2018-10-17T11:57:23.423000-04:00
2187644 POLITICAL CAPITAL, LLC 2f46c19b-1356-4499-a782-d7823988eab9 Q3 POLITICAL CAPITAL, LLC 401104260 PINE PHARMACEUTICALS 2018 third_quarter PHA Outsourcing Facilities HR-2871 Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2018-10-17T11:59:27.970000-04:00
2187654 POLITICAL CAPITAL, LLC 0ae2520a-f588-4f15-8a90-5071b7557352 3A POLITICAL CAPITAL, LLC 401104260 MEDISCA INC 2018 third_quarter PHA DQSA Oversight HR 2871 Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-10-17T12:00:31.327000-04:00
2187731 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 53ff5d4a-7b58-4db4-add1-3fb380f871ea Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2018 third_quarter PHA HR 1409, Cancer Drug Coverage Parity Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2018-10-17T12:31:04.207000-04:00
2187748 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 10f276ac-ee6f-4630-928d-ec9d41e16227 Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2018 third_quarter PHA Issues related to the 340B drug discount program and drug pricing policies Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-10-17T12:33:08.427000-04:00
2187752 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8bf2619a-1bde-4988-918b-9b7539dbc07a Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2018 third_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2018-10-17T12:34:09.927000-04:00
2188280 KOUNTOUPES DENHAM CARR & REID, LLC 50690d7e-0f1e-4c39-a91f-ee85b36a493b Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) 2018 third_quarter PHA Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-10-17T14:40:25.143000-04:00
2188339 MASSACHUSETTS MEDICAL SOCIETY b1b0f078-166f-48f0-95d9-06d8763605f9 Q3 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2018 third_quarter PHA S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions. Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   60000 0 0 2018-10-17T14:55:45.677000-04:00
2188355 MEHLMAN CONSULTING, INC. ecba87b6-1ca0-4bbf-9898-5102d592af6b Q3 MEHLMAN CONSULTING, INC. 284950 AMERICA'S HEALTH INSURANCE PLANS 2018 third_quarter PHA Prescription drug pricing. H.R. 2212 - The CREATES Act. H.R. 1892 - Bi-partisan Budget Act of 2018; Medicare donut hole coverage. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-10-17T14:59:52.413000-04:00
2188377 FTI GOVERNMENT AFFAIRS ca822f23-328e-4672-b33e-1bb4616eb35e Q3 FTI GOVERNMENT AFFAIRS 401054971 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2018 third_quarter PHA Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)). Monitor H.R.2871 "Preserving Patient Access to Compounded Medication Act of 2017. " HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-10-17T15:01:58.130000-04:00
2188962 ASCENSION HEALTH 8bdea3c4-5eef-4cca-9767-71496f5523e3 Q3 ASCENSION HEALTH 53301 ASCENSION HEALTH 2018 third_quarter PHA Drug pricing; Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES) FAIR Drug Pricing Act; Drug pricing; 340B Drug Discount Program; Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)   490000 0 0 2018-10-17T16:18:42.077000-04:00
2189044 THERMO FISHER SCIENTIFIC INC. b035eb8e-9c57-463e-8112-1f9666bf733a Q3 THERMO FISHER SCIENTIFIC INC. 323251 THERMO FISHER SCIENTIFIC INC 2018 third_quarter PHA Drug shortage prevention Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Commerce, Dept of (DOC),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Food & Drug Administration (FDA),General Services Administration (GSA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),SENATE,State, Dept of (DOS),Veterans Affairs, Dept of (VA),White House Office   230000 0 0 2018-10-17T16:38:00.407000-04:00
2189132 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 46b8e9db-d97a-4d1a-8098-b39a749ecac6 Q3 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2018 third_quarter PHA Congressional Oversight of 340 B Program; Issues related to FDA implementation of The Drug Quality and Security Act related to the regulations of pharmacy compounding; Biosimilar naming; H.R. 421 Allowing Greater Access to Safe and Effective Contraception Act; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017; HR 749, Lower Drug Costs through Competition Act; EPA Proposed Rule: Management Standards for Hazardous Waste Pharmaceuticals Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),SENATE,Small Business Administration (SBA),Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office   290000 0 0 2018-10-17T16:57:24.270000-04:00
2189209 THE D MAJOR GROUP 7902221c-3005-4343-b5b7-1464f5398b6e Q3 THE D MAJOR GROUP 401103162 ALLERGAN INC (FORMERLY ACTAVIS INC ) 2018 third_quarter PHA Monitor issues concerning bioequivalence standards for pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2018-10-17T17:16:37.977000-04:00
2189297 BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. a944eced-bed6-48ea-8090-61558ea52b0c Q3 BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. 323876 BLUE CROSS AND BLUE SHIELD OF KANSAS INC 2018 third_quarter PHA Opioid Epidemic HOUSE OF REPRESENTATIVES,SENATE     0 0 2018-10-17T17:48:03.040000-04:00
2189320 DAN BURTON INTERNATIONAL LLC 43fb86bc-341f-42c6-8d7f-0962de2d7590 Q3 DAN BURTON INTERNATIONAL LLC 401103789 GRANULES USA INC. 2018 third_quarter PHA Consultant shall pursue an effort to obtain from the United States Food and Drug Administration (FDA) expeditious processing of Client's petition to allow additional sources of API, the active ingredient in ibuprofen, to enter the American market in order to alleviate an anticipated shortage. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-10-17T18:36:12.610000-04:00
2189399 JOHN T. DOOLITTLE, LLC 1c9b722c-89ba-445e-9fcc-5e34f95be6f3 Q3 JOHN T. DOOLITTLE, LLC 400635920 DAN BURTON INTERNATIONAL LLC ON BEHALF OF GRANULES USA INC. 2018 third_quarter PHA Consultant shall pursue an effort to obtain from the United States Food and Drug Administration (FDA) expeditious processing of Client's petition to allow additional sources of API, the active ingredient in ibuprofen, to enter the American market in order to alleviate an anticipated shortage. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-10-17T20:01:36.947000-04:00
2189513 FORGE FEDERAL AFFAIRS LLC 50d4ee4f-01ea-485a-b9ab-f7f4819825c5 Q3 FORGE FEDERAL AFFAIRS LLC 400865535 LILLY USA LLC 2018 third_quarter PHA Issues related to pricing of prescription drugs. Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-10-17T22:26:17.507000-04:00
2189756 THE MATHIS HARPLE GROUP 38fca3c8-8682-43c1-a6b7-8ca2e45a1150 Q3 THE MATHIS HARPLE GROUP 322911 PHRMA 2018 third_quarter PHA Medicare Pt D Donut Hole, USMCA Trade, CHARGE IN Legislation HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-10-18T09:19:51.790000-04:00
2189760 HOLLAND & KNIGHT LLP 047c58f6-a948-4068-9027-84b0595a04b5 Q3 HOLLAND & KNIGHT LLP 18466 PROTECTING ACCESS TO PAIN RELIEF COALITION 2018 third_quarter PHA Advocating for policy to ensure patient access to pain relief; S.2680, Opioid Crisis Response Act of 2018; H.R. 6, SUPPORT for Patients and Communities Act. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-10-18T09:21:54.617000-04:00
2189888 RUBICON ADVISORS, LLC cc43d4ef-4ee5-4b3b-9934-3efd2f3fabe5 3T RUBICON ADVISORS, LLC 315091 ALBANY MOLECULAR RESEARCH INC. 2018 third_quarter PHA Border Adjustment tax HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 1 2018-10-18T09:46:52.043000-04:00
2189911 RUBICON ADVISORS, LLC d8380637-79d6-4e86-999a-ec8ea76801eb Q3 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2018 third_quarter PHA Prescription Drug User Fee HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2018-10-18T09:49:01.607000-04:00
2189922 RUBICON ADVISORS, LLC 53f8389c-ce29-45ac-b76e-64371bc00b18 Q3 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2018 third_quarter PHA Prescription Drug User Fee Act (PDUFA) reauthorization. Generic Drug User Fee Act (GDUFA) reauthorization. Border Adjustment Tax (BAT) issues Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 45000   0 0 2018-10-18T09:52:08.403000-04:00
2189942 RUBICON ADVISORS, LLC 684cfbcf-efa8-4348-aa60-765cf25f28e5 Q3 RUBICON ADVISORS, LLC 315091 CONSCIOUS DISCIPLINE 2018 third_quarter PHA Medicare HOUSE OF REPRESENTATIVES,SENATE 37500   0 0 2018-10-18T09:54:18.247000-04:00
2189959 RUBICON ADVISORS, LLC 77e5eae0-eda9-4dc7-9abe-25b351271374 Q3 RUBICON ADVISORS, LLC 315091 LANNETT COMPANY, INC 2018 third_quarter PHA Medicare and Medicaid, Generic Prescription HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2018-10-18T09:56:23.793000-04:00
2189961 HOLLAND & KNIGHT LLP 9947f386-a194-4fb8-998f-d4927fed7315 Q3 HOLLAND & KNIGHT LLP 18466 THE BIOSIMILARS FORUM 2018 third_quarter PHA Medicare reimbursement issues, FDA regulation of biosimilars. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2018-10-18T09:56:24.450000-04:00
2190075 ELI LILLY AND COMPANY 7a570846-1e6c-4c69-872f-e5ef10bab449 Q3 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2018 third_quarter PHA Hospital discounts; 340B program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   1930000 0 0 2018-10-18T10:15:00.513000-04:00
2190510 PRIME THERAPEUTICS 30330e10-872d-4654-9364-d426204fc19c Q3 PRIME THERAPEUTICS 400339576 PRIME THERAPEUTICS 2018 third_quarter PHA S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D; provisions added through amendment to H.R. 6 that limit who can use analgesic prescribing guidelines(became HR 6, which is awaiting President's signature). S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices (now PL 115-263). H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5958: The Phair Pricing Act of 2018, provisions related to the use of quality provisions and provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.6144: Know the Lowest Price Act -provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. H.R.5675: To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries; provisions mandating a Medicare lock-in program for Medicare beneficiaries at risk for opioid abuse. HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2018-10-18T10:53:29.830000-04:00
2190615 NVG, LLC 4c432625-bfe9-415e-931a-5600fd28358e Q3 NVG, LLC 76833 MANATT, PHELPS AND PHILLIPS, LLP (ON BEHALF OF NEKTAR THERAPEUTICS) 2018 third_quarter PHA FDA oversight of certain pain reliever products. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-10-18T11:05:09.427000-04:00
2190756 GREATER NEW YORK HOSPITAL ASSOCIATION 51d9ed68-3fe9-4726-a7aa-6bbeeac7f970 Q3 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2018 third_quarter PHA Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases, including raising awareness about saline and local anesthetic shortages. Oppose legislation that would harm the 340B Drug Discount Program for safety net hospitals and support legislation to prevents the implementation of the cuts in CMS Final 2017 OPPS Rule (CMS-2017-0091), the SERV Communities Act (support) (H.R. 6071) and H.R. 4392 (support). Support reforms aimed at creating more competition in the generic drug market, including ending pay for delay (S.124), and support other pro-competition policies, including legislation that would prohibit evergreening and abuse of citizen petitions, and promote the growth of biosimilars. Supported legislation to increase competition in the drug marketplace and prevent REMS abuses, the CREATES Act (S. 974/H.R.2214) (support). Raise awareness about generic injectable opioid shortages, urge engagement by the Food & Drug Administration Office of Drug Shortages and approval by the Drug Enforcement Agency of CII quota requests to increase production of injectable opioid products in short supply. Submitted comments to DEA urging the revision of its quota allocation process to recognize the unique institutional needs for injectable opioids. Submitted comments to DEA opposing proposed aggregate quota reductions for CY 2018 Schedule II controlled substances. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office   600000 0 0 2018-10-18T11:25:07.227000-04:00
2191022 BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC 972b33a7-e7ce-4adf-9ac2-64e43ebee295 Q3 BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC 401104621 BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC 2018 third_quarter PHA HR 5202 - Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 , S. 916 - Protecting Patient Access to Emergency Medications Act of 2017: To amend the Controlled Substances Act to provide for the delivery of a controlled substance by a pharmacy to an administering practitioner. S.2680 - Opioid Crisis Response Act of 2018, H.R.5176 - Preventing Overdoses While in Emergency Rooms Act of 2018, H.R.6 - SUPPORT for Patients and Communities Act - all relevant sections pertaining to opioid crisis HOUSE OF REPRESENTATIVES,SENATE   130000 0 0 2018-10-18T12:02:41.350000-04:00
2191161 BALLARD PARTNERS b5828d74-1c73-4143-8aa7-47de815d63a2 Q3 BALLARD PARTNERS 401104288 LABORATORY CORPORATIONS OF AMERICA HOLDINGS 2018 third_quarter PHA Clinical Lab Rates White House Office 80000   0 0 2018-10-18T12:24:55.247000-04:00
2191331 ACG ADVOCACY 3ebbb685-419a-47c1-a18f-93ed3bcc1979 Q3 ACG ADVOCACY 2057 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2018 third_quarter PHA Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. Issues regarding direct and indirect renumeration under Medicare Part D plans. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-10-18T13:07:59.787000-04:00
2191422 MEHLMAN CONSULTING, INC. d0fb72fe-fe23-4cbc-8b7b-82edb74c4520 Q3 MEHLMAN CONSULTING, INC. 284950 ASCENSION HEALTH ALLIANCE 2018 third_quarter PHA Prescription drug pricing. S. 974 - CREATES Act of 2017. 340B Drug Pricing Program. H.R. 6 - SUPPORT for Patients and Communities Act. S. 3120 - HEAL Act of 2018. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-10-18T13:18:26.677000-04:00
2191442 MEHLMAN CONSULTING, INC. 40784b93-c6f8-4cf6-8e47-74c39a3039c8 Q3 MEHLMAN CONSULTING, INC. 284950 THE CAMPAIGN FOR SUSTAINABLE RX PRICING 2018 third_quarter PHA Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D Biosimilars. H.R.6 - SUPPORT for Patients and Communities Act. S. 2553: Know the Lowest Price Act of 2018. S. 2554: Patient Right to Know Drug Prices Act. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-10-18T13:23:32.600000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2427.788ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API